OBJECTIVE： To provide reference for rational use of antituberculosis drugs and reduce the occurrence of ADR in multiple-drug resistance tuberculosis （MDR-TB） patients. METHODS： TB inpatients were selected from our hospital during Feb. 2012-May 2015， and then divided into suspected MDR-TB group （202 cases） and diagnosed MDR-TB group （162 cases）. According to the patient’s condition， different treatment management modes were chosen， and the incidence of ADR were observed. Treatment and management period of 2 groups were 18 months. RESULTS： In suspected MDR-TB group， the drug resistance rates to first line drugs were greater than or equal to 26.24％， among which drug resistance rates to isoniazid and rifampicin were about 40％. Resistance rates to second line-drugs were greater than or equal to 4.95％， among which resistance rate to protionamide was the highest， being 46.04％. The results of drug sensitivity tests showed that 44.06％ of patients were sensitive to all first-line drugs， 14.36％ of patients were resistant to single drug， 9.90％ of patients were usually resistant to drugs and 31.68％ of patients were resistant to multiple drugs. 21.78％ of patients were sensitive to all first-line drugs and second-line drugs， 24.75％ of patients were resistant to single drug， 17.82％ of patients were usually resistant to drugs， 32.67％ of patients were resistant to multiple drugs and 2.97％ of patients were extensively resistant to drugs. In the management plan of MDR-TB patients therapy， 56.17％ were treated in tuberculosis control institutions； referral to special hospital for treatment accounted for 14.81％； 22.22％ didn’t receive any treatment； other factors lead to a change in treatment or unable to continue to treat accounted for 6.79％. The incidence of ADR in MDR-TB patients was higher than suspected MDR-TB patients， there was statistical significance between 2 groups （P＜0.05）. After the following symptomatic treatment， all patients were improved. CONCLUSIONS： For patients with MDR-TB， according to disease condition， appropriate treatment management program can be found so as to improve therapeutic efficacy， reduce the incidence of ADR， control spreading and development of tubercle bacillus.